ArticlesEffects of zoledronic acid versus CLODRONIC ACID (cas 10596-23-3) on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
-
Add time:08/17/2019 Source:sciencedirect.com
SummaryBackgroundBisphosphonates are the standard of care for reducing the risk of skeletal-related events in patients with bone lesions from multiple myeloma. The MRC Myeloma IX study was designed to compare the effects of zoledronic acid versus CLODRONIC ACID (cas 10596-23-3) in newly diagnosed patients with multiple myeloma. Here, we report the secondary outcomes relating to skeletal events.
We also recommend Trading Suppliers and Manufacturers of CLODRONIC ACID (cas 10596-23-3). Pls Click Website Link as below: cas 10596-23-3 suppliers
Prev:ArticlesFirst-line treatment with zoledronic acid as compared with CLODRONIC ACID (cas 10596-23-3) in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Next:Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel partial amides of CLODRONIC ACID (cas 10596-23-3)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- X-ray diffraction study of bisphosphonate metal complexes: Mg, Sr and Ba complexes of (dichloromethylene)bisphosphonic acid P,P′-dibenzoyl anhydride08/20/2019
- X-ray diffraction study of polymeric Mg complexes of CLODRONIC ACID (cas 10596-23-3)08/19/2019
- Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel partial amides of CLODRONIC ACID (cas 10596-23-3)08/18/2019
- ArticlesFirst-line treatment with zoledronic acid as compared with CLODRONIC ACID (cas 10596-23-3) in multiple myeloma (MRC Myeloma IX): a randomised controlled trial08/16/2019
- Determination of impurities in CLODRONIC ACID (cas 10596-23-3) by anion-exchange chromatography08/15/2019
- Clinical efficacy of CLODRONIC ACID (cas 10596-23-3) in horses diagnosed with navicular syndrome: A field study using objective and subjective lameness evaluation08/14/2019
-
Health and Chemical more >